* BELLUS Health Inc BLU.TO is expected to show a fall in
quarterly revenue when it reports results on March 6
(estimated).
* The Laval Quebec-based company is expected to report a
8.2% decrease in revenue to $3.67 thousand from $4 thousand a
year ago, according to the mean estimate from 3 analysts, based
on Refinitiv data.
* Refinitiv's mean analyst estimate for BELLUS Health Inc
is for
a loss of 18 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for BELLUS
Health Inc
is C$22, above its last closing price of C$10.30.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2022 -0.15 -0.16 -0.20 Missed -21.2
Jun. 30 2022 -0.16 -0.17 -0.18 Missed -2.9
Mar. 31 2022 -0.18 -0.20 -0.13 Beat 35
Dec. 31 2021 -0.23 -0.22 -0.18 Beat 17.5
Sep. -0.22 -0.21 -0.29 Missed -36.5
30 2021
Jun. 30 2021 -0.20 -0.20 -0.23 Missed -12.2
Mar. 31 2021 -0.11 -0.11 -0.20 Missed -73.9
Dec. 31 2020 -0.11 -0.10 -0.10 Met 3.8
This summary was machine generated March 3 at 11:10 GMT. All
figures in US dollars unless otherwise stated